Infinata Announces BioPharm Clinical™ Launch™ as a Global Trial Planning Solution Exclusively for Smaller and Mid-Size Pharmas and Biotechs

Share Article

Cost-accessible online analytics platform provides study timeline and enrollment forecasts by region for companies with a specific development focus

In order to support the global planning requirements of clinical operations teams at smaller and mid-size pharmaceutical and biotechnology companies, Infinata has introduced BioPharm Clinical™ Launch™ as a valuable and cost-accessible premium analytics solution intended for less robust development pipelines.

Launch provides access to exclusive analytics available in BioPharm Clinical, including its innovative Study Advisor™ feature, to help companies plan programs by leveraging the industry’s largest tracked pool of 150,000 global studies. By inputting trial parameters such as indication, location and specific inclusion/exclusion criteria, users will generate reports forecasting milestone timelines, enrollment expectations and more by region. These reliable analytics enable clinical operations teams to plan more effectively and efficiently, reducing both time and risk while optimizing the trial’s chance for success.

“BioPharm Clinical is the undisputed gold standard for study planning and investigator and site selection, used by top pharmaceutical companies and CROs around the world,” said Ruth McHenry, Managing Director of Infinata. “At the same time, we understand that many smaller companies have more focused demands than large pharmas with pipelines spanning multiple diverse therapeutic areas. With Launch, we are excited to fill a need in the industry for a full-featured and efficient solution tailored to the needs of those clinical teams dedicated to individual promising drug candidates.”

To learn more, qualifying companies can sign up for a free preview and trial account of BioPharm Clinical Launch.

About BioPharm Clinical

BioPharm Clinical is an exclusive support solution for clinical operations professions, providing real-time trial analytics and the most comprehensive database of sites and investigators. Clients benefit from proprietary calculations tailored to their particular trial requirements, detailed milestone timelines and more as they make critical study feasibility assessments and evaluate investigators for their global programs. Learn more at

About Infinata, Inc.

Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. Find more information at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kristopher Sarajian
Email >
Visit website